Comparing Oncotype DX Recurrence Score Categories with Immunohistochemically Defined Luminal Subtypes
| Autor: | Junichi Yamada, Yuko Inoue, Naoko Takeda, Hiroshi Seto, Yoshio Mizuno, Kazuhiko Sato, Hiromi Fuchikami |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Gynecology medicine.medical_specialty medicine.diagnostic_test biology business.industry Concordance Recurrence score Estrogen receptor Small sample medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer 030220 oncology & carcinogenesis Internal medicine Ki-67 Progesterone receptor medicine biology.protein Oncotype DX business |
| Zdroj: | Journal of Cancer Therapy. :223-231 |
| ISSN: | 2151-1942 2151-1934 |
| DOI: | 10.4236/jct.2016.73023 |
| Popis: | Background: At the 13th St Gallen International Breast Cancer Conference in 2013, a new definition of luminal A-like and luminal B-like breast cancer was proposed, involving the expression of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67. We examined the rate of concordance between the risk groups using the Oncotype DX recurrence score (RS) and the previous and newly proposed luminal subtypes with the standardized Ki-67 assessment. Method: The relationship between a previously and newly proposed, immunohistochemically defined luminal A and B subtype with the Oncotype DX RS of 41 cases of T1-2 N0-1 M0 (ER positive, HER2 negative) breast cancer was assessed. We first classified the patients into the previously defined luminal A and B subtypes, according to the level of Ki-67 as either “low” ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|